Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
British Columbia Cancer Agency |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00569712 |
RATIONALE: Studying the genes expressed in samples of blood and lung fluid in the laboratory from patients receiving budesonide and formoterol may help doctors learn more about the effect of budesonide and formoterol on gene expression and biomarkers.
PURPOSE: This clinical trial is studying genes in blood and lung fluid samples from patients with chronic obstructive pulmonary disease, with or without a previous diagnosis of lung cancer, or with asthma treated with budesonide and formoterol.
Condition | Intervention |
---|---|
Lung Cancer Precancerous/Nonmalignant Condition |
Drug: budesonide/formoterol fumarate dihydrate inhalation aerosol Procedure: DNA methylation analysis Procedure: bronchoalveolar lavage Procedure: bronchoscopy Procedure: comparative genomic hybridization Procedure: gene expression profiling Procedure: immunoenzyme technique Procedure: laboratory biomarker analysis |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | A Pilot Comparative Study of the Genomic Molecular and Clinical Profiles of Patients With Lung Cancer, COPD, or Asthma Treated With Symbicort Turbuhaler |
Estimated Enrollment: | 30 |
Study Start Date: | January 2007 |
Estimated Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: Patients receive budesonide/formoterol fumarate dihydrate inhalation aerosol (Symbicort Turbuhaler) twice daily for 4 weeks in the absence of disease progression or unacceptable toxicities.
Patients undergo blood sample collection and bronchoscopy at baseline and at 4 weeks. Blood and bronchoalveolar fluid samples are analyzed for inflammatory biomarker measurements. Bronchial brushing cell samples are analyzed by comparative genomic hybridization array, whole genome methylation array, and gene expression profiling.
After completion of study treatment, patients are followed at 1 week by telephone interview.
Ages Eligible for Study: | 45 Years to 74 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Meets 1 of the following criteria:
Former smoker with a 30 pack-year smoking history and mild to moderate degree of airflow obstruction, meeting the following criterion:
Non-smoker with mild to moderate bronchial asthma not already on inhaled corticosteroids, meeting the following criterion:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Canada, British Columbia | |
British Columbia Cancer Agency - Vancouver Cancer Centre | Recruiting |
Vancouver, British Columbia, Canada, V5Z 4E6 | |
Contact: Stephen Lam, MD 604-675-8089 |
Principal Investigator: | Stephen Lam, MD | British Columbia Cancer Agency |
Study ID Numbers: | CDR0000577434, BCCA-H06-00209, ZENECA-BCCA-H06-00209 |
Study First Received: | December 6, 2007 |
Last Updated: | December 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00569712 |
Health Authority: | Unspecified |
non-small cell lung cancer precancerous/nonmalignant condition |
Thoracic Neoplasms Non-small cell lung cancer Precancerous Conditions Symbicort Budesonide Asthma Lung Diseases, Obstructive |
Respiratory Tract Diseases Lung Neoplasms Lung Diseases Formoterol Carcinoma, Non-Small-Cell Lung Pulmonary Disease, Chronic Obstructive |
Anti-Inflammatory Agents Respiratory Tract Neoplasms Respiratory System Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic beta-Agonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Asthmatic Agents |
Glucocorticoids Hormones Adrenergic Agonists Pharmacologic Actions Neoplasms Neoplasms by Site Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Bronchodilator Agents |